Overview
The Bolivian constitution guarantees public access to medicines and prioritizes domestic production of generic drugs; however, recent economic challenges have led to shortages of critical medications, as the government has not had the necessary foreign exchange to purchase adequate supplies. Each geographic department in Bolivia is responsible for its own procurement. Departments often buy large quantities of equipment and supplies at once and often favor U.S. products. Departmental governments now have a lower budget for health programs due to cuts from the central government. It is important to note that, due to the inefficiency of public healthcare services, there has been a marked increase in demand for private medical care. Consequently, the import of equipment, instruments, and medicines for this sector has grown significantly in recent years. Bolivia permits the import of medical devices and pharmaceuticals. There is no significant local production of medical devices and products, so imported products are necessary. Bolivia produces a limited number of pharmaceutical products, mainly for domestic consumption. U.S. firms should note that Bolivia lacks a specific law prohibiting brand infringement or copycat registration of pharmaceutical products but follows Decision 486 of the Andean Community (2000), which bans unauthorized use of confusingly similar trademarks that could mislead consumers. Trademark registration with the National Intellectual Property Authority (SENAPI) is required, but enforcement is weak due to limited resources and a lack of specialized IP courts. Chemical data submitted to the National Pharmacology and Health Technologies Agency (AGEMED) lacks trade secret protection, allowing generics with similar branding. The 2009 constitution prioritizes medicine access over IP rights, enabling compulsory licensing. Non-communicable diseases such as diabetes drive demand for affordable generics, complicating IP protection. See the “Protection of Property Rights” section for details.
| Production | 2022 | 2023 | 2024 |
|---|---|---|---|
| Total Local Production | 0 | 0 | 0 |
| Total Exports | 0 | 0 | 0 |
| Total Imports | 382.4 | 361.5 | 330.8 |
| Imports from the U.S. | 34.5 | 33.9 | 33.2 |
| Total Market Size | 382.4 | 361.5 | 330.8 |
| Exchange Rates | 6.86 | 6.86 | 6.86 |
(Total market size = (total local production + imports) - exports)
Units: USD
Source: National Statistics Bureau (INE)
Leading Sub-sectors
Pharmaceutical products, lab supplies, and medical devices are leading sub-sectors. There is an increasing demand for hemodialysis equipment, breast cancer scanners, and equipment to detect and treat cervical cancer.
Opportunities
The health budget increased from $3.54 billion in 2023 to 4.29 billion in 2025. The health budget prioritizes construction projects, equipment, and improvement of its facilities, including medical posts and hospitals. The budget allocates resources for the Universal Health System (SUS) and the implementation of programs for pandemic care. Due to the poor coverage of the public health system, there has been significant growth in the private health sector, which directly purchases equipment, supplies, and medicines.